Suppr超能文献

激肽在血管紧张素转换酶抑制剂心血管作用中的贡献。

Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.

作者信息

Linz W, Wiemer G, Gohlke P, Unger T, Schölkens B A

机构信息

Department of Pharmacology, Hoechst AG, Frankfurt/Main, Germany.

出版信息

Pharmacol Rev. 1995 Mar;47(1):25-49.

PMID:7784479
Abstract

From pharmacological investigations and clinical studies, it is known that ACE inhibitors exhibit additional local actions that are not related to hemodynamic changes and that cannot be explained only by interference with the renin-angiotensin system by means of an inhibition of ANG II formation. Because ACE is identical to kininase II, which inactivates the nonapeptide BK and related kinins, potentiation of kinins might be responsible for these additional effects of ACE inhibitors. ACE inhibition, concentration, and time dependently increased the formation of NO and PGI2 in cultured endothelial cells of different origin and from different species, including humans. The specific B2 kinin receptor antagonist, icatibant, suppressed the ACE inhibitor-induced increase in endothelial cyclic GMP accumulation index for NO-formation and, in parallel, attenuated the increase in PGI2 release. In renovascular models of hypertension associated with a stimulated renin-angiotensin system (two-kidney, one-clip), blood pressure reduction by ACE inhibitors was attenuated by icatibant, whereas in rats with genetic hypertension with normal to low plasma renin, blood pressure reduction through ACE inhibitors was not affected. In experimental atherosclerosis in rabbits, ACE inhibitors were able to preserve endothelial function and vascular reactivity and to reduce surface involvement. In the balloon denudation model of carotid arteries in rats, it was found that ACE inhibition markedly reduced neointima formation. However, when the ACE inhibitor was given together with icatibant, its effect was significantly blunted. Perfusion with ACE inhibitors induced a reduction of the incidence, as well as of the duration, of ventricular fibrillation and improved cardiodynamics and myocardial metabolism. BK perfusion induced comparable cardioprotective effects. In addition, perfusion with ACE inhibitors markedly increased the outflow of BK and related kinins from isolated rat hearts. The antiischemic effect of ACE inhibitors and BK were abolished by the addition of L-NNA (1 x 10(-6) mol/l) or icatibant (1 x 10(-9) mol/l). Similar results were found in dogs and rabbits with myocardial infarction. BK and related kinins also seem to be involved in preconditioning and remodeling. The effect of ACE inhibition in LVH was investigated in rats made hypertensive by aortic banding. ACE inhibition with ramipril, in the antihypertensive dose of 1 mg/kg/day for 6 weeks, prevented the increase in blood pressure and the development of LVH. A lower, nonantihypertensive dose of the ACE inhibitor (10 micrograms/kg/day for 6 weeks) had no effect on the increase in blood pressure or on plasma ACE activity, but also prevented LVH after aortic banding.4+ off

摘要

从药理学研究和临床研究可知,血管紧张素转换酶(ACE)抑制剂具有一些额外的局部作用,这些作用与血流动力学变化无关,且不能仅通过抑制血管紧张素II(ANG II)的形成来干扰肾素-血管紧张素系统来解释。由于ACE与激肽酶II相同,激肽酶II可使九肽缓激肽(BK)和相关激肽失活,因此激肽的增强可能是ACE抑制剂这些额外作用的原因。ACE抑制作用、浓度和时间依赖性地增加了来自不同来源和不同物种(包括人类)的培养内皮细胞中一氧化氮(NO)和前列环素(PGI2)的生成。特异性B2激肽受体拮抗剂艾替班特抑制了ACE抑制剂诱导的内皮细胞环鸟苷酸(cGMP)积累指数增加以促进NO生成,同时减弱了PGI2释放的增加。在与激活的肾素-血管紧张素系统相关的高血压肾血管模型(两肾一夹)中,艾替班特减弱了ACE抑制剂的降压作用,而在血浆肾素正常至较低的遗传性高血压大鼠中,ACE抑制剂的降压作用未受影响。在兔实验性动脉粥样硬化中,ACE抑制剂能够维持内皮功能和血管反应性,并减少表面累及。在大鼠颈动脉球囊剥脱模型中,发现ACE抑制作用显著减少了新生内膜的形成。然而,当ACE抑制剂与艾替班特一起给药时,其作用明显减弱。用ACE抑制剂灌注可降低室颤的发生率和持续时间,并改善心脏动力学和心肌代谢。BK灌注诱导了类似的心脏保护作用。此外,用ACE抑制剂灌注显著增加了BK和相关激肽从离体大鼠心脏的流出。添加L-硝基精氨酸甲酯(L-NNA,1×10⁻⁶mol/L)或艾替班特(1×10⁻⁹mol/L)可消除ACE抑制剂和BK的抗缺血作用。在心肌梗死的犬和兔中也发现了类似结果。BK和相关激肽似乎也参与了预处理和重塑过程。在通过主动脉缩窄使大鼠高血压的模型中研究了ACE抑制在左心室肥厚(LVH)中的作用。以1mg/kg/天的降压剂量用雷米普利进行ACE抑制6周,可预防血压升高和LVH的发展。较低剂量的非降压性ACE抑制剂(10μg/kg/天,6周)对血压升高或血浆ACE活性无影响,但也可预防主动脉缩窄后的LVH。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验